The podcast episode looks at the investigational drug and the obesity and related conditions it is being studied for, beyond weight alone.
Recap by typeshit. Post by @circleoffriendsclub on Instagram.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
A search listing on comparing tirzepatide and semaglutide as weight loss drugs in 2026. No article text came with it, so details are unclear.
Hollis talks through the investigational obesity drug and asks what the research could mean beyond the number on the scale.
Loading…